Global Health Uganda Trials

Global Health Uganda	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Green, Nancy

BRAIN Safe II, NCT04750707: Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II )

Active, not recruiting

270

RoW

Hydroxyurea, Siklos

Global Health Uganda LTD, Columbia University, University of Pittsburgh, Emory University, Mulago Hospital, Uganda, Makerere University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Sickle Cell Anemia in Children

06/24

PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer

Active, not recruiting

1145

Europe, Canada, Japan, US, RoW

177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT

Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.

Prostatic Neoplasms

07/25

02/26

SPRINTS, NCT03653676: Sickle Cell Pro-Inflammatory Response to Interval Training Study

Recruiting

N/A

140

Exercise Test (CIIT)

Ann & Robert H Lurie Children's Hospital of Chicago, University of Illinois at Chicago, St. Jude Children's Research Hospital, Columbia University, University of California, Irvine

Sickle Cell Disease

03/22

12/22

Idro, Richard

BRAIN Safe II, NCT04750707: Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II )

Active, not recruiting

270

RoW

Hydroxyurea, Siklos

Sickle Cell Anemia in Children

06/24



	Diseases Companies Products Productz Mechanisms of Action Sites